Abstract
Mesenchymal stem cells (MSCs) exert potent immuno-regulatory activities on various immune cells and also differentiate into various mesodermal lineages besides retaining a distinct self-renewal ability. Such exclusive characteristics had enabled MSCs to be recognised as an ideal source for cell-based treatment in regenerative medicine and immunotherapy. Thus, considering MSCs for treating degenerative disease of organs with limited regenerative potential such as cartilage would serve as an ideal therapy. This study explored the feasibility of generating human cartilage-derived MSCs (hC-MSCs) from sports injured patients and characterised based on multipotent differentiation and immunosuppressive activities. Cartilage tissues harvested from a non-weight bearing region during an arthroscopy procedure were used to generate MSCs. Despite the classic morphology of fibroblast-like cells and a defined immunophenotyping, MSCs expressed early embryonic transcriptional markers (SOX2, REX1, OCT4 and NANOG) and differentiated into chondrocytes, adipocytes and osteocytes when induced accordingly. Upon co-culture with PHA-L activated T-cells, hC-MSCs suppressed the proliferation of the T-cells in a dose-dependent manner. Although, hC-MSCs did not alter the activation profile of T cells significantly, yet prevented the entering of activated T cells into S phase of the cell cycle by cell cycle arrest. The present study has strengthened the evidence of tissue-resident mesenchymal stem cells in human cartilage tissue. The endogenous MSCs could be an excellent tool in treating dysregulated immune response that associated with cartilage since hC-MSCs exerted both immunosuppressive and regenerative capabilities.
This is a preview of subscription content, log in via an institution to check access.
Abbreviations
- MSCs:
-
Mesenchymal stem cells
References
Alsalameh S, Amin R, Gemba T, Lotz M (2004) Identification of mesenchymal progenitor cells in normal and osteoarthritic human articular cartilage. Arthritis Rheumatol 50:1522–1532. https://doi.org/10.1002/art.20269
Chambers I, Colby D, Robertson M, Nichols J, Lee S, Tweedie S, Smith A (2003) Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell 113:643–655
Cho KJ, Trzaska KA, Greco SJ, McArdle J, Wang FS, Ye JH, Rameshwar P (2005) Neurons derived from human mesenchymal stem cells show synaptic transmission and can be induced to produce the neurotransmitter substance P by interleukin-1 alpha. Stem Cells 23:383–391. https://doi.org/10.1634/stemcells.2004-0251
Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, Uccelli A (2006) Human mesenchymal stem cells modulate B-cell functions. Blood 107:367–372. https://doi.org/10.1182/blood-2005-07-2657
Csaki C, Schneider PR, Shakibaei M (2008) Mesenchymal stem cells as a potential pool for cartilage tissue engineering. Ann Anat 190:395–412. https://doi.org/10.1016/j.aanat.2008.07.007
Dazzi F, Ramasamy R, Glennie S, Jones SP, Roberts I (2006) The role of mesenchymal stem cells in haemopoiesis. Blood Rev 20:161–171. https://doi.org/10.1016/j.blre.2005.11.002
De Bari C, Dell’Accio F, Tylzanowski P, Luyten FP (2001) Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis Rheumatol 44:1928–1942
Detterline AJ, Goldberg S, Bach BR Jr, Cole BJ (2005) Treatment options for articular cartilage defects of the knee. Orthop Nurs 24:361–366 (quiz 367–368)
Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Horwitz E (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy 8:315–317
Gronthos S, Zannettino AC, Hay SJ, Shi S, Graves SE, Kortesidis A, Simmons PJ (2003) Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow. J Cell Sci 116:1827–1835
Huangfu D, Maehr R, Guo W, Eijkelenboom A, Snitow M, Chen AE, Melton DA (2008a) Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol 26:795–797. https://doi.org/10.1038/nbt1418
Huangfu D, Osafune K, Maehr R, Guo W, Eijkelenboom A, Chen S, Melton DA (2008b) Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol 26:1269–1275. https://doi.org/10.1038/nbt.1502
Javazon EH, Beggs KJ, Flake AW (2004) Mesenchymal stem cells: paradoxes of passaging. Exp Hematol 32:414–425. https://doi.org/10.1016/j.exphem.2004.02.004
Jones EA, Kinsey SE, English A, Jones RA, Straszynski L, Meredith DM, McGonagle D (2002) Isolation and characterization of bone marrow multipotential mesenchymal progenitor cells. Arthritis Rheumatol 46:3349–3360. https://doi.org/10.1002/art.10696
Jones EA, Crawford A, English A, Henshaw K, Mundy J, Corscadden D, McGonagle D (2008) Synovial fluid mesenchymal stem cells in health and early osteoarthritis: detection and functional evaluation at the single-cell level. Arthritis Rheumatol 58:1731–1740
Kolf CM, Cho E, Tuan RS (2007) Mesenchymal stromal cells. Biology of adult mesenchymal stem cells: regulation of niche, self-renewal and differentiation. Arthr Res Ther 9:204. https://doi.org/10.1186/ar2116
Kuroda T, Tada M, Kubota H, Kimura H, Hatano SY, Suemori H, Tada T (2005) Octamer and Sox elements are required for transcriptional cis regulation of Nanog gene expression. Mol Cell Biol 25:2475–2485. https://doi.org/10.1128/MCB.25.6.2475-2485.2005
Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, Ringden O (2004) Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363:1439–1441. https://doi.org/10.1016/S0140-6736(04)16104-7
Le Blanc K, Samuelsson H, Gustafsson B, Remberger M, Sundberg B, Arvidson J, Ringden O (2007) Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 21:1733–1738. https://doi.org/10.1038/sj.leu.2404777
Lee SY, Nakagawa T, Reddi AH (2009) Mesenchymal progenitor cells derived from synovium and infrapatellar fat pad as a source for superficial zone cartilage tissue engineering: analysis of superficial zone protein/lubricin expression. Tissue Eng Part A 16:317–325
Otto W, Rao J (2004) Tomorrow’s skeleton staff: mesenchymal stem cells and the repair of bone and cartilage. Cell Prolif 37:97–110
Palermo AT, LaBarge MA, Doyonnas R, Pomerantz J, Blau HM (2005) Bone marrow contribution to skeletal muscle: a physiological response to stress. Dev Biol 279:336–344
Peng L, Jia Z, Yin X, Zhang X, Liu Y, Chen P, Zhou C (2008) Comparative analysis of mesenchymal stem cells from bone marrow, cartilage, and adipose tissue. Stem cells Dev 17:761–774. https://doi.org/10.1089/scd.2007.0217
Pesce M, Scholer HR (2001) Oct-4: gatekeeper in the beginnings of mammalian development. Stem Cells 19:271–278. https://doi.org/10.1634/stemcells.19-4-271
Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Marshak DR (1999) Multilineage potential of adult human mesenchymal stem cells. Science 284:143–147
Quirici N, Soligo D, Bossolasco P, Servida F, Lumini C, Deliliers GL (2002) Isolation of bone marrow mesenchymal stem cells by anti-nerve growth factor receptor antibodies. Exp Hematol 30:783–791
Ramasamy R, Fazekasova H, Lam EW, Soeiro I, Lombardi G, Dazzi F (2007a) Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation 83:71–76. https://doi.org/10.1097/01.tp.0000244572.24780.54
Ramasamy R, Lam EW, Soeiro I, Tisato V, Bonnet D, Dazzi F (2007b) Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth. Leukemia 21:304–310. https://doi.org/10.1038/sj.leu.2404489
Ramasamy R, Tong CK, Seow HF, Vidyadaran S, Dazzi F (2008) The immunosuppressive effects of human bone marrow-derived mesenchymal stem cells target T cell proliferation but not its effector function. Cell Immunol 251:131–136. https://doi.org/10.1016/j.cellimm.2008.04.009
Rasmusson I, Uhlin M, Le Blanc K, Levitsky V (2007) Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes. J Leukoc Biol 82:887–893. https://doi.org/10.1189/jlb.0307140
Rogers MB, Hosler BA, Gudas LJ (1991) Specific expression of a retinoic acid-regulated, zinc-finger gene, Rex-1, in preimplantation embryos, trophoblast and spermatocytes. Development 113:815–824
Sakaguchi Y, Sekiya I, Yagishita K, Muneta T (2005) Comparison of human stem cells derived from various mesenchymal tissues: superiority of synovium as a cell source. Arthritis Rheumatol 52:2521–2529
Su W, Zhang H, Jia Z, Zhou C, Wei Y, Hu S (2006) Cartilage-derived stromal cells: is it a novel cell resource for cell therapy to regenerate infarcted myocardium? Stem Cells 24:349–356
Tabera S, Perez-Simon JA, Diez-Campelo M, Sanchez-Abarca LI, Blanco B, Lopez A, San Miguel JF (2008) The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes. Haematologica 93:1301–1309. https://doi.org/10.3324/haematol.12857
Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663–676. https://doi.org/10.1016/j.cell.2006.07.024
Tokcaer-Keskin Z, Akar AR, Ayaloglu-Butun F, Terzioglu-Kara E, Durdu S, Ozyurda U, Akcali KC (2009) Timing of induction of cardiomyocyte differentiation for in vitro cultured mesenchymal stem cells: a perspective for emergencies. Can J Physiol Pharmacol 87:143–150. https://doi.org/10.1139/Y08-111
Tyndall A, Walker UA, Cope A, Dazzi F, De Bari C, Fibbe W, Feldmann M (2007) Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005. Arthr Res Ther 9:301. https://doi.org/10.1186/ar2103
Vellasamy S, Tong CK, Azhar NA, Kodiappan R, Chan SC, Veerakumarasivam A, Ramasamy R (2016) Human mesenchymal stromal cells modulate T-cell immune response via transcriptomic regulation. Cytotherapy 18:1270–1283
Wu R, Gu B, Zhao X, Tan Z, Chen L, Zhu J, Zhang M (2013) Derivation of multipotent nestin(+)/CD271 (-)/STRO-1 (-) mesenchymal-like precursors from human embryonic stem cells in chemically defined conditions. Hum Cell 26:19–27. https://doi.org/10.1007/s13577-011-0022-3
Yamanaka S (2008) Induction of pluripotent stem cells from mouse fibroblasts by four transcription factors. Cell Prolif 41:51–56. https://doi.org/10.1111/j.1365-2184.2008.00493.x
Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Thomson JA (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science 318:1917–1920. https://doi.org/10.1126/science.1151526
Acknowledgements
This project supported by Research University Grant Scheme (RUGS) 04-02-12-1757RU and 04/02/10/0920RU by Universiti Putra internal grant scheme. The postgraduate student, Pratheep Sandrasaigaran partially supported by special research graduate scheme by Universiti Putra Malaysia.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sandrasaigaran, P., Algraittee, S.J.R., Ahmad, A.R. et al. Characterisation and immunosuppressive activity of human cartilage-derived mesenchymal stem cells. Cytotechnology 70, 1037–1050 (2018). https://doi.org/10.1007/s10616-017-0182-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10616-017-0182-4